Healthcare services provider Clover Health Investments Corp. (CLOV), which offers Medicare Advantage plans for American seniors, yesterday announced financial results for its second quarter ended June 30, 2021.
The company's CEO Vivek Garipalli stated, "Clover took another step in its journey to improve every life with the launch of Direct Contracting this past quarter. This milestone more than doubled our revenue and nearly doubled lives under Clover Assistant management. . .We have ambitious goals to maintain an aggressive growth trajectory while pursuing our mission to improve every life by making great healthcare available and affordable to all American seniors regardless of health, wealth or economic status."
Clover Health's President and CTO Andrew Toy commented, "The Clover Assistant continues to be a key differentiator which underpins our unique model. The Clover Assistant has approximately 95,000 lives under management and is on pace to manage over $1 billion of annualized revenue. Most importantly, we believe the Clover Assistant drives better outcomes for our members."
The company's CFO Joe Wagner discussed recent financial results at Clover and advised that revenue in Q2/21 increased by 139.7% to $412.5 million, compared to $172.1 million in Q2/20. Wagner noted the increase was due largely to its launch of direct contracting and added that based on results achieved in Q2/21, the firm is now operating at a $1.6 billion annual revenue run rate.
Clover listed that Q2/21 revenue included $195.4 million in Medicare Advantage (MA) premiums and $216.4 million in Direct Contracting (DC) revenue, compared to $170.3 million in MA premiums and no DC revenue in Q2/20.
The company advised that as of June 30, 2021, it had total lives under management of approximately 129,000, an increase of 126.3% over the number at the end of Q2/20. The Q2/21 total included 66,566 MA membership lives and 62,025 DC lives.
Clover incurred a GAAP net loss of $317.6 million in Q2/21, compared to a net income of $5.4 million in Q2/20.
The company stated that "its second quarter 2021 results were impacted by a non-cash loss of $134.5 million relating to the change in the fair value of its public and private placement warrants."
The firm further reported a non-GAAP adjusted EBITDA loss of $138.7 million and a non-GAAP, normalized adjusted EBITDA loss of $58.0 million, which it said reflects the impact from the COVID-19 pandemic.
The company stated that, as measured by lives under management, its Clover Assistant platform continues to grow, having increased around 229% year-over-year to approximately 95,000. The firm indicated that Clover Assist is now on pace to track and manage more than $1 billion in revenue on a 12-month basis.
The company offered some forward guidance and indicated the for FY/21 it expects total revenues will be in the range of $1.4-1.5 billion. The firm advised that these levels reflect estimated MA revenue of $760-790 million and Medicare Direct Contracting revenue of $650-700 million.
Clover stated it expects that by the end of December 2021, MA membership will grow by 17-21% year-over-year to somewhere between 68,000-70,000. The firm noted that for the Medicare DC program, the number of aligned beneficiaries will remain relatively flat for the rest of 2021 but is expected to increase significantly starting in January 2020.
The company indicated that for FY/21 it estimates that it will post a normalized Non-GAAP Adjusted EBITDA loss of between $210-250 million.
Clover Health is a next-generation Medicare Advantage (MA) insurer based in Nashville, Tenn. The company uses its "flagship" Clover's Assistant software platform to provide senior citizens in the U.S. with relevant and affordable health plans. The Clover platform provides doctors with personalized data-driven information at the point of care that helps improve clinical decision-making, resulting in better patient outcomes. The firm's plans are presently available to seniors enrolled in Medicare in 11 U.S. states. These plans may include coverage for hospitalizations, ER and doctor visits, and pharmacy coverage as well as coverage for dental, hearing and vision.
Clover Health has a market cap of around $3.3 billion with approximately 408.1 million shares outstanding. CLOV shares opened 17% higher today at $9.52 (+$1.39, +17.10%) over yesterday's $8.13 closing price. The stock has traded today between $8.58 to $9.65 per share and closed at $9.01 (+$0.88, +10.82%).
[NLINSERT]
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
